Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd

SZSE:301130.SZ

28.32 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

2025 Q22025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 76.09352.21963.82463.61260.86165.19553.60756.40958.64755.4471.25467.58963.51953.10678.86870.68573.87662.22782.65981.24175.1747.248
Cost of Revenue 15.79412.30217.52514.80616.19714.64415.67410.7939.72810.54114.78412.0311.289.32412.91411.95711.9039.92912.74312.09311.1147.961
Gross Profit 60.29939.91746.29948.80644.66450.55137.93345.61648.91944.89956.4755.55952.23843.78365.95458.72861.97452.29869.91669.14864.05639.288
Gross Profit Ratio 0.7920.7640.7250.7670.7340.7750.7080.8090.8340.810.7930.8220.8220.8240.8360.8310.8390.840.8460.8510.8520.832
Reseach & Development Expenses 3.0272.6460.1992.9162.9574.1533.4732.1681.5651.4947.6461.2011.2791.6173.1842.2733.9284.5311.3191.1260.960.96
General & Administrative Expenses -3.9168.861-12.72817.207-1.715.955-8.78212.879-2.4516.1784.24312.528-2.2115.4671.4867.6593.7714.227-50.46111.34.0014.001
Selling & Marketing Expenses 23.4919.80825.20932.57426.82928.66229.54628.79932.08329.39936.43836.5433.14327.51442.29638.73635.96132.30544.15548.7735.80135.801
SG&A 19.57328.6712.48149.78132.15634.61733.00741.67829.63335.57740.50549.06830.93132.98143.78346.39539.75536.531-6.30660.0739.50339.503
Other Expenses 19.637-0.26126.959-14.997-0.389-0.071-0.073-0.028-0.118-0.001-4.197-0.001-0.021-1.006-0.0261.071-47.236-40.321-5.7330-47.816-30.743
Operating Expenses 42.23831.05539.63937.735.50239.54836.5533728.64437.73143.95444.95538.65235.38746.59146.419-47.236-40.32147.75955.486-47.816-30.743
Operating Income 18.0618.8626.66111.1069.16211.0031.3812.55224.36611.04312.51613.81915.6110.18419.92913.02614.73811.97719.8814.57916.248.544
Operating Income Ratio 0.2370.170.1040.1750.1510.1690.0260.2230.4150.1990.1760.2040.2460.1920.2530.1840.1990.1920.2410.1790.2160.181
Total Other Income Expenses Net -0.00600.885-0-0.501-0.2032.8092.403-0.118-0.001-0.67-0.001-0.021-1.006-0.026-0.136-1.531-0-0.0680-0.048-0.2
Income Before Tax 18.0568.8627.54511.10611.76116.10210.49912.52424.24711.04211.84513.81815.5899.17919.90312.88914.43811.97719.81214.57916.1928.344
Income Before Tax Ratio 0.2370.170.1180.1750.1930.2470.1960.2220.4130.1990.1660.2040.2450.1730.2520.1820.1950.1920.240.1790.2150.177
Income Tax Expense 2.2311.211.3431.4911.3532.0591.2911.5533.4991.4663.2422.4342.7591.2732.0361.821.9271.4043.2732.212.4340
Net Income 16.658.2946.2029.61510.40914.0439.20810.97120.7489.5758.60311.38412.837.90617.86711.0712.5110.57216.53912.36913.7587.077
Net Income Ratio 0.2190.1590.0970.1510.1710.2150.1720.1940.3540.1730.1210.1680.2020.1490.2270.1570.1690.170.20.1520.1830.15
EPS 0.220.110.080.130.140.170.110.140.260.120.110.140.160.120.220.140.190.170.20.240.170.12
EPS Diluted 0.220.110.080.130.140.170.110.140.260.120.110.140.160.120.220.140.190.170.20.240.170.12
EBITDA 18.1898.9977.55811.12217.96216.12415.23117.20928.86115.65510.99718.45320.15913.74824.01317.06619.15116.6924.93318.767-16.45839.288
EBITDA Ratio 0.2390.1720.1180.1750.2950.2470.2840.3050.4920.2820.1540.2730.3170.2590.3040.2410.2590.2680.3020.231-0.2190.832